# Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD

> **NCT06924710** · NA · RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 286 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Standard Therapy
- **OTHER:** Adaptive Therapy

## Key facts

- **NCT ID:** NCT06924710
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-06
- **Primary completion:** 2029-06-15
- **Final completion:** 2029-12-31
- **Target enrollment:** 286 (ESTIMATED)
- **Last updated:** 2025-10-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06924710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06924710, "Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06924710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*